Apixaban Study Compared Risks in Kidney Disease Patients
A study published in September 2026 analyzed stroke and bleeding risks for patients with advanced chronic kidney disease.
Updated on Sept. 28, 2026 in Heart Disease
Live Poll
Do you trust new medical study findings to guide your healthcare decisions with your doctor?
A September 2026 study in JAMA Network Open evaluated the risks of apixaban versus warfarin and nonuse in patients with atrial fibrillation and stage 4-5 chronic kidney disease. Researchers identified that apixaban use was associated with lower rates of ischemic stroke and major bleeding compared to warfarin.
Why it matters
The study aimed to inform clinical decision-making regarding the use of anticoagulants in patients with advanced chronic kidney disease who are not receiving dialysis. These findings provide evidence on the relative safety profiles of commonly prescribed blood thinners for this vulnerable population.
The cohort included 14,712 new apixaban users, 6,335 warfarin users, and 21,005 nonusers. Compared to nonuse, apixaban resulted in a major bleeding hazard ratio of 1.32.
The players
JAMA Network Open
This is a peer-reviewed, open-access medical journal that publishes research on clinical and public health topics.
The details
Using a 3-group target trial emulation framework, investigators analyzed Medicare fee-for-service claims and Optum Clinformatics data to track outcomes. The researchers applied propensity-score matching to isolate the effects of the anticoagulants in patients with advanced kidney disease not undergoing dialysis.
Timeline
Medicare claims data covered the period from 2013 to 2022.
Optum data covered the period from 2013 through February 2025.
The research findings were published in September 2026.
Health Landscape
This research provides new empirical evidence that extends the current clinical decision-making guidelines for anticoagulation in chronic kidney disease. It highlights how retrospective analysis of claims data can bridge evidence gaps where randomized clinical trials may be difficult to conduct.
Patients with advanced chronic kidney disease and atrial fibrillation should consult their healthcare provider to discuss how these findings influence their specific treatment plan. This study clarifies the relative safety of anticoagulation options to help minimize risks of major bleeding and stroke.
The takeaway
Anticoagulation management in patients with advanced kidney disease requires careful consideration of both stroke and bleeding risks. Physicians and patients can use this data to weigh the benefits of apixaban against traditional alternatives like warfarin.
Further reading
For additional context on cardiovascular health management, visit the Heart Disease section.
More information
Review the full JAMA Network Open study article for detailed methodology and findings.
Source note: This article includes information reported by Renal and Urology News.
Live Poll
Do you trust new medical study findings to guide your healthcare decisions with your doctor?
